# ada-panda-mini
*A minimal, reproducible simulation of ADA drug interference and PandA correction.*

ğŸ‘‰ For background on why ADA assays matter, case studies, pharma workflows, and the role of data science, see [introduction.md](introduction.md).

![Banner](banner.png)

---

## ğŸš€ Executive Summary
**Problem**  
Standard ADA assays underestimate immunogenicity at therapeutic drug levels due to drug interference.  

**Solution**  
This repo simulates PandA (PEG + Acid) correction, showing how it restores ADA detection, improves drug tolerance, and reduces assay bias.  

**Impact**  
Demonstrates how bioanalytical method choice affects PK, exposureâ€“response, and dose justification, with outputs formatted for regulatory reports and digital health standards.  

---

## ğŸ”¬ Purpose
- **Drug interference**: Therapeutic drug in serum can mask anti-drug antibodies (ADA) in bridging immunoassays, causing false negatives.  
- **PandA method**: PEG precipitation + Acid dissociation overcomes this interference and achieves high drug tolerance in ADA detection.  

This repo provides a **minimal reproducible simulation** of:
1. How drug interference biases ADA recovery in a standard assay  
2. How PandA-style correction restores ADA detection  
3. How this difference propagates to PK exposure, target attainment, and dose recommendations  
4. How results align with literature benchmarks and regulatory expectations  

---

## ğŸ“š Literature Anchors
- **Zoghbi et al., 2015** â€“ Original PandA paper, PEG + acid achieves high drug tolerance (PMID: 26255760)  
- **FDA Immunogenicity Assay Guidance (2019)** â€“ Assay validation, drug tolerance, tiered testing  
- **Celerion Poster (2020)** â€“ PandA detects 10 ng/mL ADA at 800 Âµg/mL drug  
- **Sanofi EBF 2024** â€“ Practical defaults: 6% PEG precip, 3% PEG wash, 300 mM acetic acid, 30â€“45 min  

---

## ğŸ§ª Method Overview
### PandA critical steps
1. **Complex formation** â€“ Drug saturates ADA  
2. **PEG precipitation** â€“ Pellet complexes (6% PEG)  
3. **Acid dissociation** â€“ Acetic acid 300â€“500 mM, pH 2.5â€“3.5, 30â€“45 min  
4. **Detection** â€“ ECL anti-Ig detection, optimized blockers  

**Trade-offs**  
- Too strong acid or â‰¥60 min â†’ ADA denaturation (signal loss)  
- PandA chosen for drug tolerance â‰¥100 Âµg/mL; bridging alone suffices only for low Âµg/mL  

---

## ğŸ“Š What this repo simulates
### Notebooks
- **01_simulate** â€“ Generate synthetic PK profiles, ADA status, assay recovery curves  
- **02_measure** â€“ Apply drug-dependent masking (standard vs PandA assay detection)  
- **03_exposure_response** â€“ Show downstream impact on PK troughs, ADA detection, and exposureâ€“response  
- **04_benchmark_vs_literature** â€“ Compare simulated recovery vs published benchmarks; flag PASS/ALERT  

### Outputs (in `/reports`)
- **Parquet files**  
  - `tlgs.parquet`: tolerance + bias metrics  
  - `benchmarks.parquet`: PASS/ALERT flags  
- **Figures**  
  - Drug tolerance curve  
  - ADA time series (true vs measured vs PandA)  
  - Detection bias vs drug concentration  
  - Exposureâ€“response plots  
  - PASS/ALERT table  

---

## ğŸ› ï¸ Method Parameters (defaults)
- PEG_precip: 6% (cold)  
- PEG_wash: 3% (Ã—2)  
- Acid: Acetic acid 300 mM, pH 2.8â€“3.2  
- Acid_time: 30â€“45 min  

Tuning guide included in code comments.  

---

## ğŸ§¾ Validation Metrics (aligned to FDA 2019)
- Sensitivity (LLOQ ADA)  
- Drug tolerance (â‰¥80% recovery threshold)  
- Target interference  
- Specificity (drug inhibition confirmatory)  
- Precision (intra-/inter-assay CVs)  
- Cut-points (SCP, CCP)  

---

## â–¶ï¸ How to run
```bash
git clone https://github.com/YOURNAME/ada-panda-mini
cd ada-panda-mini
mamba env create -f env.yml
mamba activate ada-panda
make all   # runs notebooks 01 â†’ 04, saves figures + parquet outputs
```
Outputs will appear in /reports.

## ğŸ“ˆ Results

- **Drug tolerance curves** â€“ Standard fails above ~10 Âµg/mL; PandA passes up to ~500â€“1000 Âµg/mL  
- **ADA time series** â€“ PandA restores ADA detection masked by standard assays  
- **Bias vs drug concentration** â€“ Standard shows strong negative bias; PandA corrects  
- **Exposureâ€“response** â€“ PandA shows true clearance effects, ADA+ patients with lower troughs  
- **PASS/ALERT benchmarks** â€“ PandA passes FDA-style drug tolerance; standard triggers ALERT  

---

## ğŸ§¾ Summary

- **Assay artifact**: Standard bridging assays underestimate ADA at therapeutic levels  
- **Solution**: PandA improves drug tolerance and reduces bias  
- **Downstream impact**: Corrected ADA detection changes PK/PD and dose justification  
- **Regulatory alignment**: Reflects FDA/EMA expectations to document drug tolerance validation  

---
## ğŸ“‚ Repo structure
```bash
ada-panda-mini/
â”œâ”€â”€ notebooks/
â”‚   â”œâ”€â”€ 01_simulate.ipynb
â”‚   â”œâ”€â”€ 02_measure.ipynb
â”‚   â”œâ”€â”€ 03_exposure_response.ipynb
â”‚   â”œâ”€â”€ 04_benchmark_vs_literature.ipynb
â”œâ”€â”€ reports/
â”‚   â”œâ”€â”€ figures/
â”‚   â”œâ”€â”€ tlgs.parquet
â”‚   â”œâ”€â”€ benchmarks.parquet
â”œâ”€â”€ env.yml
â”œâ”€â”€ introduction.md
â”œâ”€â”€ README.md
```
---

## ğŸ“¬ Contact
Carlos Montefusco
ğŸ“§ cmontefusco@gmail.com
ğŸ”— GitHub: /camontefusco
